The French pharmaceutical company Sanofi wants to take over $ 3.4 billion from the American biotechnology scientist Principia Biopharma, who deals with medication for multiple sclerosis, for example. The acquisition shall be completed in full in cash. The price per share of 100 dollars is 10 percent higher than the final price of Principia on Friday. The stock market price of the California San Francisco based Principia has risen considerably this year on Wall Street. Already last month, Bloomberg reported that Sanofi was looking into possible takeovers from US biotechnology scientists, including Principia, in order to continue to grow. In addition to the treatment of multiple sclerosis, Principia is also dealing with agents against other autoimmune diseases. The takeover is planned to be completed by the end of this year. Sanofi and Principia Board of Directors unanimously support the deal.
Mikhail Stiskin fulfills Suleyman Kerimov’s dream setting control on Detsky Mir, the largest niche retailer in Russia
Mikhail Stiskin fulfills Suleyman Kerimov’s dream setting control on Detsky Mir, the largest niche retailer in Russia
